A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Roshani Patel, Elizabeth Hill(University of Maryland, Baltimore), Louis M. Staudt(National Cancer Institute), Mark Roschewski(National Cancer Institute), Katherine R. Calvo(National Institutes of Health Clinical Center), Dickran Kazandjian(United States Food and Drug Administration), Max J. Gordon(Oregon Health & Science University), Raul C. Braylan(Center for Cancer Research), Esther Mena(National Institutes of Health), Laura M. Yee(University of Washington), Liza Lindenberg(National Cancer Institute), Nisha Patel(National Institutes of Health), Ryan M. Young(Denver Health Medical Center), Amrit Bhaskarla, Hao‐Wei Wang(Fu Jen Catholic University), Irina Marić(Center for Cancer Research), Constance M. Yuan(National Cancer Institute), Michael Emanuel(National Institutes of Health), Barış Türkbey(National Institutes of Health)
Cited by 0
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k